Mark Searcey

Summary

Affiliation: University of London
Country: UK

Publications

  1. ncbi Duocarmycins--natures prodrugs?
    Mark Searcey
    Department of Pharmaceutical and Biological Chemistry, University of London School of Pharmacy, 29 39 Brunswick Square, London, WC1N 1AX, UK
    Curr Pharm Des 8:1375-89. 2002
  2. ncbi Design and synthesis of a DNA-crosslinking azinomycin analogue
    Maxwell A Casely-Hayford
    Dept of Pharmaceutical and Biological Chemistry, School of Pharmacy, University of London, 29 39 Brunswick Square, London, UK WC1N 1AX
    Org Biomol Chem 3:3585-9. 2005
  3. ncbi Bisintercalator natural products with potential therapeutic applications: isolation, structure determination, synthetic and biological studies
    Simon Dawson
    Department of Pharmaceutical and Biological Chemistry, School of Pharmacy, University of London, 29 39 Brunswick Square, London, WC1N 1AX, UK
    Nat Prod Rep 24:109-26. 2007
  4. ncbi Development of nonsymmetrical 1,4-disubstituted anthraquinones that are potently active against cisplatin-resistant ovarian cancer cells
    Klaus Pors
    Department of Pharmaceutical and Biological Chemistry, The School of Pharmacy, University of London, 29 39 Brunswick Square, London
    J Med Chem 48:6690-5. 2005
  5. ncbi Resistance in cancer: a target for drug discovery
    Mark Searcey
    Department of Pharmaceutical and Biological Chemistry, School of Pharmacy, University of London, 29 39 Brunswick Square, London WC1N 1AX, UK
    Curr Med Chem Anticancer Agents 4:457-60. 2004
  6. ncbi Truncated azinomycin analogues intercalate into DNA
    Maxwell A Casely-Hayford
    Department of Pharmaceutical and Biological Chemistry, School of Pharmacy, University of London, 29 39 Brunswick Square, London WC1N 1AX, UK
    Bioorg Med Chem Lett 15:653-6. 2005
  7. ncbi Synthesis of distamycin A polyamides targeting G-quadruplex DNA
    Michael J B Moore
    Cancer Research UK Biomolecular Structure Group, The School of Pharmacy, University of London, 29 39 Brunswick Square, London, UK WC1N 1AX
    Org Biomol Chem 4:3479-88. 2006
  8. ncbi Solid-phase synthesis of chlorofusin analogues
    Esther C Y Woon
    Department of Pharmaceutical and Biological Chemistry, The School of Pharmacy, University of London, 29 39 Brunswick Square, London WC1N 1AX
    J Org Chem 72:5146-51. 2007
  9. ncbi Efficient solid-phase-based total synthesis of the bisintercalator TANDEM
    John P Malkinson
    Department of Pharmaceutical and Biological Chemistry, School of Pharmacy, University of London, 29 39 Brunswick Square, London WC1N 1AX, UK
    J Org Chem 70:7654-61. 2005
  10. ncbi Solid-phase synthesis of the cyclic peptide portion of chlorofusin, an inhibitor of p53-MDM2 interactions
    John P Malkinson
    Department of Pharmaceutical and Biological Chemistry, School of Pharmacy, University of London, 29 39 Brunswick Square, London WC1N 1AX, UK
    Org Lett 5:5051-4. 2003

Collaborators

Detail Information

Publications17

  1. ncbi Duocarmycins--natures prodrugs?
    Mark Searcey
    Department of Pharmaceutical and Biological Chemistry, University of London School of Pharmacy, 29 39 Brunswick Square, London, WC1N 1AX, UK
    Curr Pharm Des 8:1375-89. 2002
    ..A simple analysis of the approaches that could be taken to vary the structure for targeting is suggested...
  2. ncbi Design and synthesis of a DNA-crosslinking azinomycin analogue
    Maxwell A Casely-Hayford
    Dept of Pharmaceutical and Biological Chemistry, School of Pharmacy, University of London, 29 39 Brunswick Square, London, UK WC1N 1AX
    Org Biomol Chem 3:3585-9. 2005
    ..These observations will be important in the design of further azinomycin analogues with antitumour activity...
  3. ncbi Bisintercalator natural products with potential therapeutic applications: isolation, structure determination, synthetic and biological studies
    Simon Dawson
    Department of Pharmaceutical and Biological Chemistry, School of Pharmacy, University of London, 29 39 Brunswick Square, London, WC1N 1AX, UK
    Nat Prod Rep 24:109-26. 2007
    ..One of the more recently identified marine natural products that is moving close to clinical development is thiocoraline, and it therefore seems timely to review the various bisintercalator natural products...
  4. ncbi Development of nonsymmetrical 1,4-disubstituted anthraquinones that are potently active against cisplatin-resistant ovarian cancer cells
    Klaus Pors
    Department of Pharmaceutical and Biological Chemistry, The School of Pharmacy, University of London, 29 39 Brunswick Square, London
    J Med Chem 48:6690-5. 2005
    ..8 and its chloropropyl analogue 13 retained significant activity against human A2780/cp70 xenografted tumors in mice...
  5. ncbi Resistance in cancer: a target for drug discovery
    Mark Searcey
    Department of Pharmaceutical and Biological Chemistry, School of Pharmacy, University of London, 29 39 Brunswick Square, London WC1N 1AX, UK
    Curr Med Chem Anticancer Agents 4:457-60. 2004
    ..It is suggested that the view of the solid tumour as a complex organ rather than a collection of individual cells will inform future drug development and both overcome and target multiple resistance mechanisms...
  6. ncbi Truncated azinomycin analogues intercalate into DNA
    Maxwell A Casely-Hayford
    Department of Pharmaceutical and Biological Chemistry, School of Pharmacy, University of London, 29 39 Brunswick Square, London WC1N 1AX, UK
    Bioorg Med Chem Lett 15:653-6. 2005
    ..Both the designed azinomycin analogue 4 and the natural product 3 bind to DNA and cause unwinding, supporting an intercalative mode of binding...
  7. ncbi Synthesis of distamycin A polyamides targeting G-quadruplex DNA
    Michael J B Moore
    Cancer Research UK Biomolecular Structure Group, The School of Pharmacy, University of London, 29 39 Brunswick Square, London, UK WC1N 1AX
    Org Biomol Chem 4:3479-88. 2006
    ..Quadruplex affinity increases with the number of pyrrole groups, and it is suggested that this is consistent with a mixed groove/G-quartet stacking binding mode...
  8. ncbi Solid-phase synthesis of chlorofusin analogues
    Esther C Y Woon
    Department of Pharmaceutical and Biological Chemistry, The School of Pharmacy, University of London, 29 39 Brunswick Square, London WC1N 1AX
    J Org Chem 72:5146-51. 2007
    ..This suggests that the full chromophore structure may be required for activity...
  9. ncbi Efficient solid-phase-based total synthesis of the bisintercalator TANDEM
    John P Malkinson
    Department of Pharmaceutical and Biological Chemistry, School of Pharmacy, University of London, 29 39 Brunswick Square, London WC1N 1AX, UK
    J Org Chem 70:7654-61. 2005
    ..This efficient synthesis sets the stage for a study of the structure-activity relationship of TANDEM and the natural product triostin A, with analogues containing "point mutations" at every site within the cyclic compounds...
  10. ncbi Solid-phase synthesis of the cyclic peptide portion of chlorofusin, an inhibitor of p53-MDM2 interactions
    John P Malkinson
    Department of Pharmaceutical and Biological Chemistry, School of Pharmacy, University of London, 29 39 Brunswick Square, London WC1N 1AX, UK
    Org Lett 5:5051-4. 2003
    ..Initial biological assays, using an immunofluorescence method, suggest that the compounds are not cytotoxic but do not inhibit the p53/mdm2 interaction. [structure: see text]..
  11. ncbi Synthesis of DNA-directed pyrrolidinyl and piperidinyl confined alkylating chloroalkylaminoanthraquinones: potential for development of tumor-selective N-oxides
    Klaus Pors
    Institute of Cancer Therapeutics, University of Bradford, West Yorkshire, BD7 1DP, United Kingdom
    J Med Chem 49:7013-23. 2006
    ..Derivatization of the potent DNA cross-linking agent 15 to an N-oxide resulted in loss of the DNA unwinding, DNA interstrand cross-linking and cytotoxic activity of the parent molecule...
  12. ncbi Chemistry in cancer research: a vital partnership
    Shana J Sturla
    Department of Medicinal Chemistry and The Cancer Center, University of Minnesota, Minneapolis, Minnesota 55455, USA
    ACS Chem Biol 2:286-92. 2007
  13. ncbi Chemistry in cancer research: a vital partnership
    Shana J Sturla
    Department of Medicinal Chemistry and The Cancer Center, University of Minnesota, Minneapolis, MN 55455, USA
    Cancer Res 67:6539-43. 2007
  14. pmc X-ray crystallographic study of DNA duplex cross-linking: simultaneous binding to two d(CGTACG)2 molecules by a bis(9-aminoacridine-4-carboxamide) derivative
    Nicholas H Hopcroft
    School of Chemistry, University of Reading Whiteknights, Reading, Berkshire RG6 6AD, UK
    Nucleic Acids Res 34:6663-72. 2006
    ....
  15. ncbi Stereoselectivity, sequence specificity and mechanism of action of the azinomycin epoxide
    Marie Hélène David-Cordonnier
    INSERM U 814, IRCL, Place de Verdun, 59045 Lille, France
    Chembiochem 7:1658-61. 2006
  16. ncbi Cancer treatments for the new millennium
    Robert Williams
    Department of Pharmaceutical and Biological Chemistry, School of Pharmacy, University of London
    Drug News Perspect 19:229-32. 2006
    ....
  17. doi DNA binding by analogues of the bifunctional intercalator TANDEM
    Andrew J Hampshire
    School of Biological Sciences, University of Southampton, UK
    Biochemistry 47:7900-6. 2008
    ..By using fragments with different lengths of [(AT) n ], we demonstrate that these ligands bind best to the center of the longer (AT) n tracts...